These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9631975)

  • 1. Serum cholesterol levels are underevaluated and undertreated.
    Danias PG; O'Mahony S; Radford MJ; Korman L; Silverman DI
    Am J Cardiol; 1998 Jun; 81(11):1353-6. PubMed ID: 9631975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of coronary calcium progression and control of lipids according to National Cholesterol Education Program guidelines.
    Wong ND; Kawakubo M; LaBree L; Azen SP; Xiang M; Detrano R
    Am J Cardiol; 2004 Aug; 94(4):431-6. PubMed ID: 15325924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy.
    Grundy SM
    Am J Cardiol; 2001 Oct; 88(7B):23J-27J. PubMed ID: 11595195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid management with statins. The lower the better?
    Laufs U; Liao JK; Böhm M
    Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lipid lowering after percutaneous coronary intervention. Intended and achieved treatment goals in real life].
    Germing A; Lindstaedt M; Mügge A
    Med Klin (Munich); 2005 Dec; 100(12):781-4. PubMed ID: 16453092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
    Klose G
    MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
    [No Abstract]   [Full Text] [Related]  

  • 7. Case reports illustrate consequences of ATP III in practice.
    Schuster H
    Am J Manag Care; 2003 Aug; Suppl():5-6. PubMed ID: 13678396
    [No Abstract]   [Full Text] [Related]  

  • 8. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 9. Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
    Gotto AM; Kuller LH
    Circulation; 2002 Jan; 105(2):136-9. PubMed ID: 11790688
    [No Abstract]   [Full Text] [Related]  

  • 10. "The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?
    Jacobson TA
    Ann Intern Med; 2000 Oct; 133(7):549-54. PubMed ID: 11015169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Breuer HW
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cholesterol synthesis inhibitors. Clinical studies on lowering coronary risk and plaque stabilization].
    Müller-Wieland D; Faust M; Krone W
    Internist (Berl); 1998 Sep; 39(9):934-42. PubMed ID: 9788115
    [No Abstract]   [Full Text] [Related]  

  • 13. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study.
    Lemaitre RN; Furberg CD; Newman AB; Hulley SB; Gordon DJ; Gottdiener JS; McDonald RH; Psaty BM
    Arch Intern Med; 1998 Sep; 158(16):1761-8. PubMed ID: 9738605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CME-Lab 2/Solution. Hypercholesteremia and therapy control].
    von Eckardstein A
    Praxis (Bern 1994); 2007 Apr; 96(17):701-2. PubMed ID: 17491201
    [No Abstract]   [Full Text] [Related]  

  • 15. Critical appraisal of revised cholesterol guidelines for the very high-risk patient.
    Rosenson R; Lloyd-Jones D;
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperlipidemia: decreasing lipid values and effects of statins].
    Mathes P
    Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
    [No Abstract]   [Full Text] [Related]  

  • 18. [Guidelines for lowering lipids are too infrequently observed. Results of a retrospective study of coronary heart disease patients].
    Klein G; Ruof J; März W; Wollschläger H; Neiss A; Wehling M
    MMW Fortschr Med; 2000 Aug; 142(35):35-7. PubMed ID: 11006705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Type 2 diabetic: risk same as after infarct. With LDL not only the quantity counts].
    MMW Fortschr Med; 2004 Jun; 146(24):4. PubMed ID: 15366509
    [No Abstract]   [Full Text] [Related]  

  • 20. [A new approach to the treatment of dyslipidemia].
    Kevelaitiene S; Slapikas R
    Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.